Qiming Venture Partners | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Qiming Venture Partners/Activity

Qiming Venture Partners Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Exit

Portfolio company NASN Intelligent Tech, an X-by-wire chassis leader Qiming co-led into in 2018, listed on the Hong Kong Stock Exchange (02261.HK).

NASN Intelligent Tech

NASN Intelligent TechQiming Venture Partners

qimingvc.comAUG 7, 2026

prnewswire.com

AUG 7, 2026

Exit

Portfolio company Attovia Therapeutics, an immune-mediated disease biotherapeutics developer, debuted on Nasdaq (ATTO).

Attovia Therapeutics

Attovia Therapeutics Qiming Venture Partners

prnewswire.comAUG 5, 2026

AUG 5, 2026

News

Managing Partner Alex Zhou debuted on the 2026 Forbes Midas List (#80) after four portfolio companies completed public listings in early 2026.

Alex Zhou named to 2026 Forbes Midas List

Qiming Venture Partners

qimingvc.comMAY 28, 2026

MAY 28, 2026

Investment

Co-led Minghui Pharmaceutical's $131M Pre-IPO financing alongside OrbiMed, taking a board seat.

Minghui Pharmaceutical

Minghui PharmaceuticalQiming Venture Partners

qimingvc.comAUG 7, 2025

AUG 7, 2025

New Fund

Announced the final closing of Fund VII at $1.2 billion, focused on early-stage Healthcare and TMT investments.

Fund VII

Qiming Venture Partners

prnewswire.comNOV 18, 2020

NOV 18, 2020